Adjuvant chemotherapy
Erdafitinib, a pan-FGFR inhibitor, in patients with metastatic or unresectable urothelial carcinoma and FGFR alterations
Although immune checkpoint inhibitors ( ICI ) have improved outcomes in some patients with Platinum-resistant metastatic urothelial carcinoma ( mUC...
FDA has approved Opdivo, a PD-1 checkpoint inhibitor, in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer
The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) injection, for intravenous use for the...
Cancer immunotherapy: Tecentriq approved in advanced bladder cancer as initial treatment for those unable to receive Cisplatin chemotherapy
The US Food and Drug Administration ( FDA ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the...
Imfinzi has received FDA accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma with disease progression during or following Platinum-containing chemotherapy
The FDA ( US Food and Drug Administration ) has granted accelerated approval to Imfinzi ( Durvalumab ). Imfinzi is...
European Union: Opdivo approved for previously treated locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior Platinum-containing therapy
The European Commission ( EC ) has approved Opdivo ( Nivolumab ) for the treatment of locally advanced unresectable or...
Management of hepatocellular carcinoma with portal vein tumor thrombus: new evidence and perspectives
Hepatocellular carcinoma ( HCC ) is responsible for over 600,000 deaths annually. In addition, hepatocellular carcinoma is characterized by its...
Atezolizumab, an anti-PD-L1 drug, for advanced bladder cancer, FDA has granted priority review
The FDA ( Food and Drug Administration ) has granted Priority Review for Atezolizumab ( anti-PD-L1; MPDL3280A ) for the...
FDA has approved Tecentriq, a PD-L1 inhibitor, for the treatment of the bladder cancer
The FDA ( Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) to treat the most common type...
Cancer immunotherapy: Tecentriq for patients with locally advanced or metastatic urothelial carcinoma
The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the...
Patients with penile squamous cell carcinoma after regional lymphadenectomy: prognostic factors of adjuvant taxane, Cisplatin, and 5-Fluorouracil chemotherapy
Little is known about the outcomes and prognostic factors of adjuvant chemotherapy for locally advanced penile squamous cell carcinoma after...
Patients with stage III colon cancer treated with Leucovorin, Fluorouracil, and Oxaliplatin with or without Cetuximab: prognostic effect of BRAF and KRAS mutations
The prognostic value of BRAF and KRAS mutations in patients who have undergone resection for colon cancer and have been...
Keytruda for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after Platinum-containing chemotherapy
The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death receptor-1...
Breast cancer adjuvant chemotherapy: Goserelin appears to protect against ovarian failure, reducing the risk of early menopause
Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone ( GnRH ) agonists...
Breast cancer patients receiving adjuvant Docetaxel and Cyclophosphamide chemotherapy: efficacy of scalp cooling in preventing chemotherapy-induced alopecia
Chemotherapy-induced alopecia ( CIA ) is a distressing adverse effect of many chemotherapy agents. The TC ( Docetaxel [ Taxotere...
Early breast cancer: activity of neoadjiuvant Lapatinib plus Trastuzumab according to PIK3CA mutations
PIK3CA mutations are common in breast cancer. The aim of a study was to evaluate the correlation of PIK3CA mutational...
HER2-positive breast cancer: PIK3CA mutations as a potential predictive marker of resistance to treatment with Lapatinib and Trastuzumab
The CHER-LOB randomized phase II study showed that the combination of Lapatinib ( Tyverb ) and Trastuzumab ( Herceptin )...
Eribulin as single agent chemotherapy for locally advanced or metastatic HER-2 negative breast cancer in patients who have progressed after at least 1 line of chemotherapy for advanced disease: data are insufficiently robust
The Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to enter the CDF...
Abraxane for first-line treatment of patients with non-small cell lung cancer, positive CHMP opinion
The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...
Immunotherapy for lung cancer: immune checkpoint regulators
Lung cancer is the number one cause of cancer mortality globally and has an estimated incidence of 1.3 million new...
Resectable colorectal liver metastasis in KRAS exon 2 wild-type patients: addition of Cetuximab to chemotherapy and surgery linked to shorter progression-free survival
Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased...